Initiator Pharma A/S (INIT.ST)
SEK 7.0
(-1.41%)
SEK 7.0
(-1.41%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 15.43 Million DKK | 22.74% |
| 2022 | 12.57 Million DKK | -5.36% |
| 2021 | 13.29 Million DKK | 0.0% |
| 2020 | - DKK | 0.0% |
| 2019 | - DKK | 0.0% |
| 2018 | - DKK | 0.0% |
| 2017 | - DKK | 0.0% |
| 2016 | - DKK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - DKK | -100.0% |
| 2024 Q2 | - DKK | 0.0% |
| 2023 Q1 | 12.7 Million DKK | 1.04% |
| 2023 FY | 15.43 Million DKK | 22.74% |
| 2023 Q4 | 15.43 Million DKK | -0.57% |
| 2023 Q3 | 15.52 Million DKK | 20.07% |
| 2023 Q2 | 12.93 Million DKK | 1.75% |
| 2022 Q2 | 13.29 Million DKK | 0.0% |
| 2022 Q3 | 13.29 Million DKK | 0.0% |
| 2022 FY | 12.57 Million DKK | -5.36% |
| 2022 Q4 | 12.57 Million DKK | -5.36% |
| 2022 Q1 | 13.29 Million DKK | 0.0% |
| 2021 FY | 13.29 Million DKK | 0.0% |
| 2021 Q2 | - DKK | 0.0% |
| 2021 Q3 | 13.02 Million DKK | 0.0% |
| 2021 Q4 | 13.29 Million DKK | 2.07% |
| 2021 Q1 | - DKK | 0.0% |
| 2020 Q2 | - DKK | 0.0% |
| 2020 Q3 | - DKK | 0.0% |
| 2020 FY | - DKK | 0.0% |
| 2020 Q4 | - DKK | 0.0% |
| 2020 Q1 | - DKK | 0.0% |
| 2019 Q2 | - DKK | 0.0% |
| 2019 FY | - DKK | 0.0% |
| 2019 Q3 | 3.47 Million DKK | 0.0% |
| 2019 Q4 | - DKK | -100.0% |
| 2019 Q1 | - DKK | 0.0% |
| 2018 Q1 | - DKK | 0.0% |
| 2018 FY | - DKK | 0.0% |
| 2018 Q4 | - DKK | 0.0% |
| 2018 Q3 | - DKK | 0.0% |
| 2018 Q2 | - DKK | 0.0% |
| 2017 Q1 | - DKK | 0.0% |
| 2017 Q4 | - DKK | 0.0% |
| 2017 Q3 | - DKK | 0.0% |
| 2017 FY | - DKK | 0.0% |
| 2017 Q2 | - DKK | 0.0% |
| 2016 Q4 | - DKK | 0.0% |
| 2016 FY | - DKK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | 4.1% |
| Ziccum AB (publ) | 857 Thousand SEK | -1701.284% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -210.042% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | 36.961% |
| Genovis AB (publ.) | 79.32 Million SEK | 80.538% |
| Intervacc AB (publ) | 181 Thousand SEK | -8428.729% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | 25.103% |
| Active Biotech AB (publ) | 3 Million SEK | -414.567% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | 74.401% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -208.74% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | 78.382% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -97.202% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -3540.802% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 85.785% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -402.834% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -498.333% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -1443.7% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 98.423% |
| Camurus AB (publ) | 24.5 Million SEK | 37.01% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | 44.0% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 98.219% |
| Cyxone AB (publ) | 858 Thousand SEK | -1699.184% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -802.221% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | 58.061% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -2217.868% |
| SynAct Pharma AB | 637 Thousand SEK | -2323.391% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -1716.118% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -776.604% |
| BioInvent International AB (publ) | 23.24 Million SEK | 33.587% |
| Alzinova AB (publ) | 800 Thousand SEK | -1829.625% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 85.503% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -1896.818% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 82.988% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | 49.671% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 93.331% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -1354.948% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |